<DOC>
	<DOCNO>NCT00583063</DOCNO>
	<brief_summary>Determine pharmacokinetic interaction rapamycin sunitinib patient advance solid tumor .</brief_summary>
	<brief_title>Interaction Study Rapamycin Sunitinib Patients With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Metastatic unresectable cancer standard treatment exist longer effective cancer evidence efficacy single agent sunitinib single agent mTOR inhibitor demonstrate Measurable nonmeasurable disease . No prior treatment 4 week start study No ongoing toxicity previous treatment 18 year old Performance status 2 good Life expectancy least 3 month . Normal organ marrow function define : No transfusion pack red blood cell within 1 week start treatment . A hemoglobin 9.0 g/dL great recommend . Patients transfuse protocol participation . Leukocytes great equal 3,000/μL Absolute neutrophil count great equal 1,500/μL Platelets great equal 100,000/μL Total bilirubin less equal 1.5 x ULN AST ALT less equal 2.5x ULN ( less equal 5x ULN liver function abnormality due underlying disease ) Creatinine within normal institutional limit OR Creatinine clearance &gt; 60 mL/min/1.73 m2 PT INR within normal institutional limit Serum calcium within normal institutional limit QTc &lt; 500 msec . Patients prior anthracycline exposure receive central thoracic radiation must NYHA class I cardiac function Must agree use adequate birth control Ability understand willingness sign write informed consent document . Prior treatment within 4 week ( 6 week nitrosoureas mitomycin C ) enter study recover adverse event due prior treatment Current treatment investigational agent . Prior therapy VEGFR mTOR inhibitor History allergic reaction attribute compound similar chemical biologic composition rapamycin sunitinib . QTc prolongation ( QTc interval equal great 500 msec ) significant ECG abnormality Uncontrolled intercurrent illness psychiatric illness/social situation would limit compliance study requirement . Patients follow condition exclude : Serious nonhealing wound , ulcer , bone fracture . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day treatment . Known active infection Major surgery radiation therapy within 4 week start study treatment . NCI CTCAE Version 3.0 grade 3 hemorrhage within 4 week start study treatment . History CVA transient ischemic attack within 12 month prior study entry . History myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within 12 month prior study entry . History pulmonary embolism within past 12 month . Class III IV heart failure define NYHA functional classification system Ongoing cardiac dysrhythmias Poorly control hypertension ( systolic blood pressure 140 mmHg high diastolic blood pressure 90 mmHg high ) Preexisting thyroid abnormality thyroid function maintain normal range medication History interstitial lung disease Patients severe immunodeficient state ( judge treat physician ) Pregnancy breastfeed . HIVpositive patient combination antiretroviral therapy ineligible potential interaction study drug Use certain medication ( determined investigator ) Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>